Sector Expert: André Uddin

Mackie Research Capital

Image: André Uddin

Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.



Recent Quotes

"As of Q1/18E, IMV had sufficient cash for operations through Q4/19."

— André Uddin, Mackie Research Capital (5/14/18)
more >

"IMV announced it has applied to list on NASDAQ."

— André Uddin, Mackie Research Capital (5/3/18)
more >

"IMV could forge licensing deals for DPX-Survivac and DPX-RSV; we are maintaining our Speculative Buy rating."

— André Uddin, Mackie Research Capital (3/20/18)
more >

"PMN is seeking to forge partnerships with big pharmas."

— André Uddin, Mackie Research Capital (3/14/18)
more >

"PMN's PMN310 demonstrated a positive signal for better efficacy."

— André Uddin, Mackie Research Capital (1/23/18)
more >

"A licensing deal for PMN's PMN310 could come in as early as 2018."

— André Uddin, Mackie Research Capital (1/4/18)
more >

"IMV is advancing DPX-NEO into a Phase 1 trial with UConn Health."

— André Uddin, Mackie Research Capital (12/7/17)
more >

"IMV reported good results of the DPX-Surivivac/epacadostat study."

— André Uddin, Mackie Research Capital (12/5/17)
more >

more comments

"IMV announced it is expanding its collaboration with Leidos to develop a DepoVax-based malaria vaccine candidate."

— André Uddin, Mackie Research Capital (11/21/17)
more >

"As of Q3/17E, PMN had $3.3M in cash and zero debt on its balance sheet; we are maintaining our Speculative Buy rating."

— André Uddin, Mackie Research Capital (11/13/17)
more >

"PMN's PMN310 has best-in-class potential to treat Alzheimer's."

— André Uddin, Mackie Research Capital (10/17/17)
more >

"We believe this newer Alzheimer's theory creates a path to develop a unique disease-modifying Alzheimer's treatment, PMN's PMN310, which has best-in-class potential."

— André Uddin, Mackie Research Capital (9/19/17)
more >

"The FDA has granted IPCI's Rexista fast track designation."

— André Uddin, Mackie Research Capital (7/13/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.